Patients aged 80+ with DLBCL show lower survival rates and higher treatment failure compared to younger groups. Older patients often have less education, live in more deprived areas, and ...

Low immunoglobulin levels affect nearly 1 in 4 newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) and significantly increase infection risk during treatment. Patients with low ...

Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...

Roche’s CD20xCD3 bispecific antibody Columvi has improved survival when used as a second-line therapy for diffuse large B-cell lymphoma (DLBCL) in a phase 3 trial, setting up regulatory filings ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

The approval of the Columvi combo, the first bispecific antibody regimen for DLBCL in Europe, follows a conditional marketing authorisation granted in July 2023 for R/R DLBCL treatment.

AbbVie and Genmab’s would-be blockbuster epcoritamab has been recommended for conditional approval in the EU as a treatment for diffuse large B-cell lymphoma (DLBCL), an aggressive form of non ...

Constitutive activation of the nuclear factor (NF)–κB pathway is essential for the survival of the least curable type of diffuse large B-cell lymphoma (DLBCL ...